AVDL (Avadel Pharmaceuticals PLC) Net earnings per one share for the last twelve months

Avadel Pharmaceuticals PLC (AVDL) - corporate logo

Risks for Avadel Pharmaceuticals (AVDL) are linked to the recognition of the drug Lumryz and patent disputes, which is confirmed by the annual EPS TTM growth measurement shown on this GURU.Markets chart, where the latest value is recorded as 99.40. Avadel Pharmaceuticals (AVDL) relies on outsourced production and logistics, while its human capital is based on highly specialized experts with a flexible bonus system.

avadel.com (AVDL) Net earnings per share (EPS TTM): for the period 02/11/2024 - 02/28/2026

Avadel Corp - analytical breakdowns and key metrics (AVDL)

- market price and analyst price targets:
- business market valuation indicators:
Fundamental valuation:Avadel Pharmaceuticals plc - AVDL
Core merchandise of Avadel Pharma

This indicator measures the rolling annual growth of earnings per share, neutralizing quarterly reporting gaps and filtering out short-term market noise to reveal the true trajectory of profitability. For Avadel Pharmaceuticals (AVDL), with its focus on costly R&D in microencapsulation, the current EPS YoY TTM growth trend serves as a marker for the efficiency of innovation commercialization and the accuracy of the business's fundamental valuation.